Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Chicago, IL
NPI: 1306028451Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Satyajit's Phone Numberphone_androidMobile
Get Satyajit's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 37 | 255 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 32 | 131 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 16 | 58 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 16 | 16 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 13 | 15 |
Authors: Richard Larson, Emily Curran, Lucy Godley, Olatoyosi Odenike, Kristen Pettit, Andrew Artz, Margaret Green, Amy Wang, Michael Thirman
Publication Date: 2018-01-05
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.
Authors: Boglarka Gyurkocza, Doris Ponce, Ying Taur, Anthony Sung, Eric Pamer, Sergio Giralt, Juliet Barker
Publication Date: 2017-03-16
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011
Lead Sponsor: Miltenyi Biotec B.V. & Co. KG
Collaborators: University of Chicago, Ohio State University, Masonic Cancer Center, University of Minnesota
Intervention / Treatment: DEVICE: Interventions
Lead Sponsor: AltruBio Inc.
Intervention / Treatment: BIOLOGICAL: Neihulizumab (ALTB-168)
